Cempra (CEMP) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cempra Provides Corporate Update and Reports Second Quarter 2017 Financial Results
August 9, 2017 8:01 AM EDTCHAPEL HILL, N.C., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment of infectious diseases, today reported financial results for the quarter ended June 30, 2017 and provided an update on recent corporate developments. The company will host a webcast and conference call today at 8:45 a.m. ET.
We have achieved significant progress with the FDA, reaching an agreement on a smaller, more focused and efficient... More
